Currently, onabotulinumtoxinA (OBT-A) is the most used prophylactic treatment for chronic migraine

The objectives of this study were to explore patient experience and perception of prophylactic treatment with OBT-A for chronic migraine

Migraines were not eliminated in most patients in this study; however, patients viewed their treatment as effective as it made it easier to manage and go about daily tasks rather than being bed-ridden because of migraines and left unable to function

This study also revealed potential barriers to treatment, which include:   - Cost of injections: this was a significant factor in the decision-making process. Cost factors were voiced by almost every patient interviewed and were even the reason for some patients discontinuing treatment   - Fear associated with side effects and needles

These qualitative data provide a more holistic perspective of patient care when treating chronic migraine and insights that may not be evident from the results of a clinical trial. These factors should be taken into consideration to inform future policy and practice